Spondyloarthropathies News

Samsung Bioepis Co. Ltd. announced the FDA has accepted for review the company’s biologics license application for SB2, a biosimilar candidate referencing infliximab, for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

DESTIN, Fla. — At the Clinical Congress of Rheumatology Annual Meeting, Robert D. Inman, MD, spoke about the current management of axial spondyloarthritis. He said one of the challenges is early diagnosis of axial spondyloarthritis.

The International Autoimmunity Summit gathered several hundred experts who span the spectrum of autoimmune diseases, which are often referred to as immune-mediated inflammatory diseases. These included many rheumatologists, as well as dermatologists, gastroenterologists, allergists and advanced practitioners who are all engaged in the care and research of these disorders.

Patients with spondyloarthritis reported difficulties in carrying out their jobs, with half reporting disability and one-third experiencing important limitations in their career perspectives, according to results.

The most highly accessed articles about pain management in rheumatology included a survey about NSAIDs. Other articles of interest highlighted fatigue associated with pain and issues related to fibromyalgia.

A new industry body, the British Biosimilars Association, has been launched to promote the use of biosimilar drug treatments in the United Kingdom, according to a press release.

Modernizing medicine, Inc. announced the launch of its modmed Electronic Medical Assistant for pain medicine, a specialty-specific, cloud-based electronic health record system with tap and touch features providing access to an anatomic atlas.

Patients with ankylosing spondylitis may not participate in social roles and may have lower satisfaction with participation in these roles, according to the results of a survey from researchers in the Netherlands and Canada.

The most highly accessed articles about biosimilars on Healio.com/Rheumatology have largely focused on the reaction to the FDA approval of the first biosimilar to infliximab in the United States.

Following FDA approval of Celltrion’s biosimilar to Janssen’s infliximab, Prime Therapeutics LLC issued a statement noting it remains “cautiously optimistic” about the future of biosimilar agents in the United States and urged regulators to finalize decisions on their use.